Literature DB >> 22156869

Early versus late surgery in patients with intestinal Behçet disease.

Yoon Suk Jung1, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon.   

Abstract

BACKGROUND: To date, no studies have been conducted to evaluate the potential benefits of early surgery in patients with intestinal Behçet disease.
OBJECTIVE: We investigated the long-term clinical outcomes in patients with intestinal Behçet disease first diagnosed at surgery ("early surgery") compared with those requiring surgical resection during the course of the disease ("late surgery").
DESIGN: This is a retrospective cohort study. SETTINGS: This study was conducted at a single tertiary academic medical center. PATIENTS: We reviewed the medical records of 272 consecutive patients with intestinal Behçet disease between March 1986 and August 2010. MAIN OUTCOME MEASURES: The cumulative probabilities of clinical recurrence and reoperation after operation were the main outcomes measures.
RESULTS: Forty of 272 patients were first diagnosed with intestinal Behçet disease at surgery (early surgery); the remaining 232 were diagnosed clinically, with 62 undergoing surgery during their follow-up after clinical diagnosis (late surgery). The cumulative probabilities of postoperative clinical recurrence and reoperation were significantly lower in the early-surgery group than in the late-surgery group (p = 0.045 and p = 0.003). In multivariate analysis, early surgery was the only independent factor significantly associated with a reduced probability of reoperation (HR 0.26; 95% CI 0.10-0.71; p = 0.008). However, when we analyzed only the patients who underwent surgery because of chronic symptoms, early surgery was not associated with lower cumulative clinical recurrence and reoperation rates (p = 0.896 and p = 0.492). LIMITATIONS: We analyzed the clinical characteristics retrospectively, and the number of patients was insufficient to reach a decisive conclusion.
CONCLUSIONS: : According to the current study, the patients with intestinal Behçet disease undergoing early surgery showed better prognoses in comparison with those undergoing late surgery. Early surgery may represent a valid approach in the initial management of the patients with intestinal Behçet disease, at least in the subset of the patients with acute symptoms.

Entities:  

Mesh:

Year:  2012        PMID: 22156869     DOI: 10.1097/DCR.0b013e318238b57e

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

Review 1.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

2.  Short- and long-term outcomes of laparoscopic surgery for intestinal Behcet's disease: a comparative study with open surgery.

Authors:  Se Jin Baek; Seung Hyuk Baik; Chang Woo Kim; Min Soo Cho; Hyun A Jang; Hyuk Hur; Byung Soh Min; Nam Kyu Kim
Journal:  Surg Endosc       Date:  2015-03-24       Impact factor: 4.584

3.  Incidence and clinical outcomes of intestinal Behçet's disease in Korea, 2011-2014: a nationwide population-based study.

Authors:  Minkyung Han; Yoon Suk Jung; Won Ho Kim; Jae Hee Cheon; Sohee Park
Journal:  J Gastroenterol       Date:  2016-12-27       Impact factor: 7.527

4.  The outcomes and risk factors of early reoperation after initial intestinal resective surgery in patients with intestinal Behçet's disease.

Authors:  Yong Eun Park; Jae Hee Cheon; Jihye Park; Ji Hoon Lee; Hyun Jung Lee; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  Int J Colorectal Dis       Date:  2016-12-27       Impact factor: 2.571

5.  C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease.

Authors:  Eun Ae Kang; Jung Won Park; Min Soo Cho; Jae Hee Cheon; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  BMC Gastroenterol       Date:  2021-10-07       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.